Is Obinutuzumab injection Jialuohua?

Obinutuzumab injection, which is marketed in China under the trade name Jia Luohua, has entered the ranks of medical insurance. Obinutuzumab is a targeted therapy drug used to treat chronic lymphocytic leukemia (CLL) and a type of non-Hodgkin lymphoma (NHL) called follicular lymphoma. Otuzumab belongs to a group of targeted therapy drugs called monoclonal antibodies, which work by targeting specific proteins (receptors). Otuzumab targets the CD20 protein on the surface of white blood cells called B lymphocytes (B cells). It then triggers the body's immune system to attack the cells and destroy them.